To determine if inhibition of MLK activity affects the viability of ER+ breast cancer cells, dose response assays were performed using the well-characterized, estrogen-sensitive MCF-7 breast cancer cell line and its estrogen-independent, antiestrogen-resistant derivative MCF-7/LCC9 (LCC9) [27]. This evidence concerns the gene MAP3K13 and breast carcinoma.